

The Future Diabetes Treatment

From traditional structures to cross-sectorial collaboration

Allan Flyvbjerg

CEO, Professor in Endocrinology, MD, DMSc

3rd Nordic Diabetic Foot Symposium, Helsinki, Finland – November 6th, 2018





Agenda


- Brief about diabetes prevalence
- •The vision behind Steno Diabetes Center Copenhagen
- Screening, treatment and prevention of diabetic foot ulcers

Agenda

- Brief about diabetes prevalence
- •The vision behind Steno Diabetes Center Copenhagen
- Screening, treatment and prevention of diabetic foot ulcers



Diabetes – a **global** challenge (IDF Atlas 2017)



Prevalence of diabetes in **Denmark**

• T1D: **0.5** % (30.000 with T1D)

• T2D: **4.5 % (**240.000 with known T2D)

• T1D+T2D: **5.0 %** (270.000 with known T1D and T2D)

• Undiagnosed T2D: **1.0** % (60.000)

• Pre-diabetes: **5.5 %** (292.000)

• Population in DK: 5.600.000



Expected increase in diabetes in **Denmark**

Increasing prevalence of 3% per year

Due to:

- Stable incidence (saturation point reached)
- Decreasing mortality (now 'only' an increased Standardized Mortality Ratio (SMR) of 50%)

Diabetes treatment in the


Capital Region of Denmark

T1D: **10%** of all diabetes patients

• T2D: **90%** of all diabetes patients

Clinical control in the hospital sector: 20% (19.000)


• Clinical control in the primary sector: **80%** (74.000)







World Diabetes Day (UN): November 14th





Australian National Diabetes Strategy 2016–2020



Agenda

- Brief about diabetes prevalence
- The vision behind Steno Diabetes Center Copenhagen
- Screening, treatment and prevention of diabetic foot ulcers



Steno Diabetes Center Copenhagen

Steno Diabetes Center Copenhagen (SDCC)

SDCC as a new Public Private Partnership (PPP)-like collaborative structure





SDCC as a new (PPP-like) collaborative structure





Private Foundations in Denmark







novo nordisk fonden

A.P. MØLLER FONDEN

CARLSBERGFONDET

H.C. Andersens Boulevard 35 · 1553 København V · Telefon 33 43 53 63





Steno Diabetes Center (SDC)

until December 31th, 2016



- SDC has treated diabetes patients since 1932 with a diabetes population of 6.000 individuals with diabetes
- SDC have had a strong international brand within diabetes treatment and research (e.g. STENO 2 Study)
- SDC has been owned by Novo Nordisk A/S until December 31th, 2016
- Over decades there has been a significant development in the health care in the Capital Region of Denmark

Unique opportunity to be a globally leading diabetes-center by a incorporation of SDC into the public health care system in the Capital Region of Denmark

A new vision developed in collaboration between the Capital Region of Denmark, the Novo Nordisk Foundation and Novo Nordisk A/S

Approval of the vision

Approval of the masterplan

SDCC launched

Spring 2015

Early considerations on various models

Summer 2015

Description of the SDCC masterplan

Description of the SDCC masterplan

SDCC launched


Rest of 2016

Establishment of SDCC

A grand total of **0.6 billion €** (4,3 billion DKK), with a donation from the **Novo Nordisk Foundation** of **0.4 billion €** (2,95 billion DKK) for the period 2017-2029



The ambition is to offer world class treatment, research, education and prevention for the benefit of the population with or at risk of diabetes



Each activity will be evaluated on **process data** (incl. PRE's), **outcome data** (incl. PRO's)





The ambition is to offer world class treatment, research, education and prevention for the benefit

of people with diabetes or at risk

CLINICAL TREATMENT World class, patient orientated, evidence based diabetes treatment 3

HEALTH PROMOTION

Research in health promotion and implementation

Individuals with diabetes


EDU State educa

profe

CLI World clinica

Each activity will be evaluated on **process data** (incl. PRE's), **outcome data** (incl. PRO's)

The ambition is to offer world class treatment, research, education and prevention for the benefit of people with diabetes or at risk



Each activity will be evaluated on process data (incl. PRE's), outcome data (incl. PRO's)





Cross-sectorial collaboration

ENSURING STANDARD TREATMENT

DEVELOPING NEW TREATMENT MODALITIES

- Follow guidelines
- Out-patient screening and treatment
- **Involvement of patients** in their own disease

- New and dedicated collaborations between various stakeholders (hospital, municipalities and general practice)
- New evidence to achieve a patientcentered approach
- Boosting the translation and implementation of health research results into daily life


Survival: Type 2-diabetes (Steno 2-study)





High amputations – data from SDCC

Type 1-diabetes

Type 2-diabetes








Jørgensen ME et al. Diabet Med. 2014; 31:443-447



The overall ambition is to **increase the quality of diabetes care for <u>all</u> individuals with diabetes** in
The Capital Region of Denmark






Steno Diabetes Copenhagen

VERSITY OF ENHAGEN

Examples of the development of new treatment modalities within diabetes in 2017-2020

- 1. Multidisciplinary collaboration in the Capital Region of Denmark on co-morbidity in diabetes within diabetic foot ulcer; diabetes and nephropathy; diabetes and cardiovascular disease
- **2. Focus on developing new tools to identify** individuals with type 1-or type 2-diabetes and psychological / psychiatric diseases
- **3. One-stop-shop-screening** for individuals with type 2-diabetes treated in GP, with a pilot project in 2018-2020
- **4. User-involvement** in treatment, clinical research, education and health care promotion activities (using PRE and PRO)

The **5 regions** in Denmark



• Capital Region of Denmark Population: 1.800.000

• Central Region of Denmark Population: 1.300.000


• Region of Southern Denmark Population: 1.200.000

• **Region Sealand** Population: 850.000

• North Denmark Region Population: 600.000



Steno Diabetes Centres in all 5 regions of Denmark



Copenhagen


- Steno centers to improve treatment quality for all danish diabetics through:
 - Regional patient treatment
 - National collaboration on research, health promotion and health care education
 - Access to the total national diabetes population allowing big scale clinical trials
- The 4 other regions to establish Steno-Centers (Region of Southern Denmark (SDCO), Central Denmark Region (SDCA) and North Denmark Region (SDCN) was launched 1.1.18. Region Sealand (SDCS) will follow 1.1.19.

UNIVERSITY OF COPENHAGEN

Agenda

- Brief about diabetes prevalence
- •The vision behind Steno Diabetes Center Copenhagen
- •Screening, treatment and prevention of diabetic foot ulcers

Prognostic studies in individuals with diabetes: Data from SDCC





Incidens of diabetic foot ulcers in type 1-diabetes: Data from SDCC


Incidence of DFU per 1000 patientyears 20 Neuropathic Neuro-ischemic Ischemic 12 Total 10 2 2003 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014

DFU per 1.000 patients per year

Diabetes Res Clin Pract. 2017 Aug;130:221-228



Incidens of diabetic foot ulcers in type 2-diabetes: Data from SDCC



DFU per 1.000 patients per year


Diabetes Res Clin Pract. 2017 Aug;130:221-228


High amputations – data from SDCC

Type 1-diabetes

Type 2-diabetes

Amputations per 1.000 patients per year





Jørgensen ME et al. Diabet Med. 2014; 31:443-447



Cross-sectorial collaboration within SDCC

ENSURING STANDARD TREATMENT

DEVELOPING NEW TREATMENT MODALITIES

- Follow guidelines
- Out-patient screening and treatment
- **Involvement of patients** in their own disease


- New and dedicated collaborations between various stakeholders (hospital, municipalities and general practice)
- New evidence to achieve a patientcentered approach
- Boosting the translation and implementation of health research results into daily life

High risk individuals with diabetes

- All individuals with actual or previous diabetic foot disease (including Charcot, other deformities or previous amputations)
- Neuropathy with vibrationvalue > 25 V or abnormal monofilament test
- Ischemia if the patient presents with DFU and ankle BP < 70 mmHg and toe BP < 50 mmHg the patient is referred to Department of Vascular Surgery at The National Hospital (Rigshospitalet))
- Nephropathy
- Visual impairment
- Elderly patients
- Co-morbidity




Screening, treatment and prevention of diabetic foot disease in The Capital Region of Denmark





The overall ambition is to **disseminate the SDCC foot care model to all hospitals** in the Capital Region of Denmark



Award: Foot of the year 2018 (Danish Podiatrists) September 20th, 2018





For further information:

Allan Flyvbjerg

CEO, Clinical professor
Steno Diabetes Center Copenhagen (SDCC)
The Capital Region of Denmark and University of Copenhagen
Niels Steensens Vej 2
DK-2820 Gentofte
Denmark
Cell +45 51779548
E-mail allan.flyvbjerg@regionh.dk

Web: www.sdcc.dk

Twitter: https://twitter.com/allanflyvbjerg



